Epigenetic modifications of chromatin in epilepsy: a potential mechanism of pharmacoresistance?

Close metadata

Recommended articles:

Experimental study of the influence of phenozanic acid and its combination with valproic acid on the development of the epileptic system. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):104-113

Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68

Epilepsy with PCDH19 mutation: polypharmacy as a consequence of the complexity and diversity of pathogenesis mechanisms. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):51-55

Study of the practice of prescribing phenosanic acid in epilepsy accompanied by asthenic disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):89-97

Personality profile caused by epilepsy according to the «Big Five» model. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):16-21

Brain microstructural abnormalities assessed by diffusion kurtosis MRI in patients with focal temporal lobe epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):171-177

Ototoxicity caused by anti-epileptic drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):14-19

Absence status epilepticus in adults. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):47-56

Comorbid anxiety disorders in patients with neurological pathology: current state of the problem and the role of etifoxine in treatment strategy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):126-136

Pharmacoresistance in epilepsy is an important problem from both clinical and fundamental perspectives. The existent hypotheses of pharmacoresistance are based on long term plastic rebuilding of the epileptic brain. One of potential mechanisms mediating such protracted changes are alterations of gene expression induced by epigenetic modifications of chromatin in brain cells of epileptic patients. Recently, changes in DNA methylation and histone post-translational modifications were reported in brain tissues of patients with pharmacoresistant epilepsy. Unfortunately, these data remain fragmentary and contradictory, therefore the results of animal models can partially fill this gap. The authors present a short review of the data concerning a potential role of epigenetic modifications in epilepsy.

Keywords:

epilepsy

pharmacoresistance

epigenetic modifications

Authors:

Sokhranyaeva L.S.

Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia

Aniol V.A.

Institut vyssheĭ nervnoĭ deiatel'nosti i neĭrofiziologii RAN;
OOO "Gerofarm";
Institut kristallografii im. A.V. Shubnikova RAN;
Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova, Moskva

Guliaeva N.V.

Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences

List of references:

Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia. 1979;20(6):729-737. https://doi.org/10.1111/j.1528-1157.1979.tb04857.x
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-319. https://doi.org/10.1056/nejm200002033420503
Schmidt D, Löscher W. Drug resistance in epilepsy: Putative neurobiologic and clinical mechanisms. Epilepsia. 2005;46(6):858-877. https://doi.org/10.1111/j.1528-1167.2005.54904.x
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2009;51(6):1069-1077. https://doi.org/10.1111/j.1528-1167.2009.02397.x
Berg AT, Langfitt J, Shinnar S, Vickrey BG, Sperling MR, Walczak T, Bazil C, Pacia SV, Spencer SS. How long does it take for partial epilepsy to become intractable? Neurology. 2003;60(2):186-190. https://doi.org/10.1212/01.wnl.0000031792.89992.ec
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ, Turk WR, Glauser TA. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62(8):1261-1273. https://doi.org/10.1212/01.wnl.0000123695.22623.32
Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain. 2002;125(1):22-31. https://doi.org/10.1093/brain/awf002
Löscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2005;2(1):86-98. https://doi.org/10.1602/neurorx.2.1.86
Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol. 1997;40(7):3-8.
Zhang Z, Wu JY, Hait WN, Yang JM. Regulation of the stability of p-glycoprotein by ubiquitination. Mol Pharmacol. 2004;66(3):395-403. https://doi.org/10.1124/mol.104.001966
Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005;46(2):224-235. https://doi.org/10.1111/j.0013-9580.2005.31904.x
Remy S, Gabriel S, Urban BW, Dietrich D, Lehmann TN, Elger CE, Heinemann U, Beck H. A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol. 2003;53:469-479. https://doi.org/10.1002/ana.10473
Vreugdenhil M, Wadman WJ. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia. 1999;40(11):1512-1522. https://doi.org/10.1111/j.1528-1157.1999.tb02034.x
Remy S, Urban BW, Elger CE, Beck H. Anticonvulsant pharmacology of voltage-gated Na+ channels in hippocampal neurons of control and chronically epileptic rats. Eur J Neurosci. 2003;17(12):2648-2658. https://doi.org/10.1046/j.1460-9568.2003.02710.x
Sharma AK, Rani E, Waheed A, Rajput SK. Pharmacoresistant epilepsy: a current update on non-conventional pharmacological and non-pharmacological interventions. J Epilepsy Res. 2015;5(1):1-8. https://doi.org/10.14581/jer.15001
Straessle A, Loup F, Arabadzisz D, Ohning GV, Fritschy JM. Rapid and long-term alterations of hippocampal GABAB receptors in a mouse model of temporal lobe epilepsy. Eur J Neurosci. 2003;18(8):2213-2226. https://doi.org/10.1046/j.1460-9568.2003.02964.x
Dalic L, Cook MJ. Managing drug-resistant epilepsy: challenges and solutions. Neuropsychiatr Dis Treat. 2016;12:2605-2616. https://doi.org/10.2147/ndt.s84852
Waddington CH. Canalization of development and the inheritance of acquired characters. Nature. 1942;3811(14):563-565. https://doi.org/10.1038/150563a0
Landgrave-Gómez J, Mercado-Gómez O, Guevara-Guzmán R. Epigenetic mechanisms in neurological and neurodegenerative diseases. Front Cell Neurosci. 2015;9:58. https://doi.org/10.3389/fncel.2015.00058
Dulac C. Brain function and chromatin plasticity. Nature. 2010;465(7299):728-735. https://doi.org/10.1038/nature09231
Goll MG, Bestor TH. Eukariotic cytosine methyltransferases. Annu Rev Biochem. 2005;74(1):481-514. https://doi.org/10.1146/annurev.biochem.74.010904.153721
Sassone-Corsi P. Physiology. When Metabolism and Epigenetics Converge. Science. 339(6116):148-150. https://doi.org/10.1126/science.1233423.
Rothbart SB, Strahl BD. Interpreting the language of histone and DNA modifications. Biochim Biophys Acta. 2014;1839(8):627-643. https://doi.org/10.1016/j.bbagrm.2014.03.001
Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403(6765):41-45. https://doi.org/10.1038/47412
Henshall DC, Kobow K. Epigenetics and Epilepsy. Cold Spring Harb Perspect Med. 2015;4(4):108-111. https://doi.org/10.1101/cshperspect.a022731
Kobow K, Blümcke I. Epigenetics in epilepsy. Neurosci Lett. 2017. https://doi.org/10.1016/j.neulet.2017.01.012
Berkovic SF, Mulley JC, Scheffer IE, Petrou S. Human epilepsies: interaction of genetic and acquired factors. Trends Neurosci. 2006;29(7):391-397. https://doi.org/10.1016/j.tins.2006.05.009
Najm I, Jehi L, Palmini A, Gonzalez-Martinez J, Paglioli E, Bingaman W. Temporal patterns and mechanisms of epilepsy surgery failure. Epilepsia. 2013;54(5):772-782. https://doi.org/10.1111/epi.12152
Jamali S, Bartolomei F, Robaglia-Schlupp A, Massacrier A, Peragut JC, Régis J, Dufour H, Ravid R, Roll P, Pereira S, Royer B, Roeckel-Trevisiol N, Fontaine M, Guye M, Boucraut J, Chauvel P, Cau P, Szepetowski P. Large-scale expression study of human mesial temporal lobe epilepsy: evidence for dysregulation of the neurotransmission and complement systems in the entorhinal cortex. Brain. 2006;129(3):625-641. https://doi.org/10.1093/brain/awl001
Kobow K, Blümcke I. The methylation hypothesis: Do epigenetic chromatin modifications play a role in epileptogenesis? Epilepsia. 2011;52(4):15-19. https://doi.org/10.1111/j.1528-1167.2011.03145.x
Dębski KJ, Pitkanen A, Puhakka N, Bot AM, Khurana I, Harikrishnan K, Ziemann M, Kaspi A, El-Osta A, Lukasiuk K, Kobow K. Etiology matters — genomic dna methylation patterns in three rat models of acquired epilepsy. Sci Rep. 2016;6(1):25668. https://doi.org/10.1038/srep25668
Miller-Delaney SFC, Bryan K, Das S, McKiernan RC, Bray IM, Reynolds JP, Gwinn R, Stallings RL, Henshall DC. Differential DNA methylation profiles of coding and non-coding genes define hippocampal sclerosis in human temporal lobe epilepsy. Brain. 2014;138(3):616-631. https://doi.org/10.1093/brain/awu373
Khudoerkov RM. Intranuclear histone changes in neurons of different types in a «mirror» epileptiform focus in the rat brain. Neurosci Behav Physiol. 1980;10(6):522-525. https://doi.org/10.1007/bf01195524
Sng JC, Taniura H, Yoneda Y. Histone modifications in kainate-induced status epilepticus. Eur J Neurosci. 2006;23(5):1269-1282. https://doi.org/10.1111/j.1460-9568.2006.04641.x
Huang Y, Doherty JJ, Dingledine R. Altered histone acetylation at glutamate receptor 2 and brain-derived neurotrophic factor genes is an early event triggered by status epilepticus. J Neurosci. 2002;22(19):8422-8428.
Park HG, Yu HS, Park S, Ahn YM, Kim YS, Kim SH. Repeated treatment with electroconvulsive seizures induces HDAC2 expression and down-regulation of NMDA receptor-related genes through histone deacetylation in the rat frontal cortex. Int J Neuropsychopharmacol. 2014;17(9):1487-1500. https://doi.org/10.1017/s1461145714000248
Huang Y, Zhao F, Wang L, Yin H, Zhou C, Wang X. Increased expression of histone deacetylases 2 in temporal lobe epilepsy: a study of epileptic patients and rat models. Synapse. 2012;66(2):151-159. https://doi.org/10.1002/syn.20995
Hoffmann K, Czapp M, Löscher W. Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases? Epilepsy Res. 2008;81(2-3):107-113. https://doi.org/10.1016/j.eplepsyres.2008.04.019
Ganesan A, Nolan L, Crabb S, Packham G. Epigenetic therapy: histone acetylation, dna methylation and anti-cancer drug discovery. Curr Cancer Drug Targets. 2009;9(8):963-981. https://doi.org/10.2174/156800909790192428
Kobow K, El-Osta A, Blümcke I. The methylation hypothesis of pharmacoresistance in epilepsy. Epilepsia. 2013;54(suppl 2):41-47. https://doi.org/10.1111/epi.12183
Baker EK, Johnstone RW, Zalcberg JR, El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene. 2005;24(54):8061-8075. https://doi.org/10.1038/sj.onc.1208955
El-Osta A, Kantharidis P, Zalcberg JR, Wolffe AP. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol. 2002;22(6):1844-1857. https://doi.org/10.1128/mcb.22.6.1844-1857.2002
Weissman B, Knudsen KE. Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res. 2009; 69(21):8223-8230. https://doi.org/10.1158/0008-5472.can-09-2166

Close metadata